Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.
| Last: | $0.0006 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $0.0006 |
| Close: | $0.0006 |
| High: | $0.0006 |
| Low: | $0.0006 |
| Volume: | 300 |
| Last Trade Date Time: | 02/27/2026 09:30:20 am |
| Market Cap: | $50,506 |
|---|---|
| Float: | 10,770,378 |
| Insiders Ownership: | 0.95% |
| Institutions: | 5 |
| Short Percent: | 300727% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.paxmedica.com |
| Country: | US |
| City: | Mahwah |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about PaxMedica Inc. (OTCMKTS: PXMD).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
